Peptide Library

FDA-approved

Sexual & reproductive

Ganirelix

Evidence

FDA approved

Class

GnRH antagonist

/

Ganirelix

KEY TAKEAWAY

Ganirelix is a ten-amino-acid synthetic GnRH antagonist used in fertility treatment. The FDA approved ganirelix in 1999 to prevent premature luteinizing hormone surges in women having controlled ovarian hyperstimulation.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

GnRH antagonist

Approved for

Preventing early ovulation during fertility treatment

Key fact

The FDA approved ganirelix in 1999 to prevent premature luteinizing hormone surges in women having controlled ovarian hyperstimulation.

Route

Daily subcutaneous injection

Evidence strength

FDA approved

What it is

What it is

Ganirelix is a ten-amino-acid synthetic GnRH antagonist used in fertility treatment.

How it works

How it works

It blocks GnRH receptors in the pituitary gland, which prevents a premature surge of luteinizing hormone.

Regulatory status

Regulatory status

The FDA approved ganirelix in 1999 to prevent premature luteinizing hormone surges in women having controlled ovarian hyperstimulation.

What it is used for

What it is used for

Preventing early ovulation during fertility treatment.

Side effects and risks

Side effects and risks

Abdominal pain, headache and injection-site reactions are reported. Ovarian hyperstimulation syndrome can occur.

Citations

Citations

U.S. FDA prescribing information for Ganirelix. DailyMed, National Library of Medicine.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo